H.I.G. Capital News
-
BRIDGEWATER, NJ - October 22, 2020 – Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today it received approval from the U.S. Food and Drug Administration (FDA) to market Ephedrine Sulfate Injection in a ready-…
-
July 8, 2020 - H.I.G. Capital Acquires Project Informatica
MILAN – July 8, 2020 – H.I.G. Europe (“H.I.G.”), the European affiliate of H.I.G. Capital, a leading global private equity investment firm with more than €34 billion of equity capital under management, announced today the acquisition by an affiliate of a controlling stake…
-
ZUG, SWITZERLAND – May 21, 2020 - Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders, today announced the publication of a key trial (013 Study) in Neurology, the official journal of the American…
-
May 13, 2020 - Leiters Awarded a Group Purchasing Agreement by Comprehensive Pharmacy Services
DENVER – May 13, 2020 - Leiters, announced today that it has entered into a strategic arrangement with the newly reorganized group purchasing organization affiliate of Comprehensive Pharmacy Services, LLC (CPS), Comprehensive Purchasing Alliance, LLC (CPA), to be the leading…
-
ZUG, SWITZERLAND – May 12, 2020 - Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders, today confirms that SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., has now made…
-
SAN DIEGO – May 12, 2020 – Neurana Pharmaceuticals, Inc., a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced the publication of a driving study which demonstrates the tolerability and safety of tolperisone in the peer-reviewed…
-
ZUG, SWITZERLAND - March 26, 2020 - Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders, today announces that the European Medicines Agency (EMA) has accepted the marketing authorization…
-
NORTHBROOK, Ill. – March 16, 2020 – Clarus Therapeutics, Inc., a commercial men’s health specialty pharmaceutical company, announced today that it has completed a senior debt financing of up to $75M. Morgan Stanley & Co. LLC acted as sole placement agent for the transaction. Clarus…
-
February 26, 2020 - Leiters Announces Facility Expansion to Increase Capacity and Accommodate Growth
DENVER – February 26, 2020 - Leiters, a trusted FDA-registered 503B provider of high-quality compounded sterile preparations, announced today its continued commitment to provide the highest quality compounded sterile preparations and pharmacy services to the healthcare market. As…
-
NORTHBROOK, Ill. – February 10, 2020 – Clarus Therapeutics, Inc. today announced that JATENZO® (testosterone undecanoate) capsules, CIII is now available by prescription in the U.S. for the treatment of appropriate men with testosterone deficiency (hypogonadism). JATENZO is…